0001213900-22-018749.txt : 20220407 0001213900-22-018749.hdr.sgml : 20220407 20220407182659 ACCESSION NUMBER: 0001213900-22-018749 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220405 FILED AS OF DATE: 20220407 DATE AS OF CHANGE: 20220407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chen Bihua CENTRAL INDEX KEY: 0001599214 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39630 FILM NUMBER: 22814945 MAIL ADDRESS: STREET 1: C/O CORMORANT ASSET MANAGEMENT, LP STREET 2: 200 CLARENDON STREET, 52ND FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MoonLake Immunotherapeutics CENTRAL INDEX KEY: 0001821586 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: DORFSTRASSE 29 CITY: ZUG STATE: V8 ZIP: 6300 BUSINESS PHONE: 41 41 510 8022 MAIL ADDRESS: STREET 1: DORFSTRASSE 29 CITY: ZUG STATE: V8 ZIP: 6300 FORMER COMPANY: FORMER CONFORMED NAME: Helix Acquisition Corp DATE OF NAME CHANGE: 20200818 4 1 ownership.xml X0306 4 2022-04-05 0 0001821586 MoonLake Immunotherapeutics MLTX 0001599214 Chen Bihua C/O HELIX ACQUISITION CORP. 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 0 0 1 0 Class A Ordinary Shares 2022-04-05 4 C 0 2785000 0 A 3215000 I See footnote Class A Ordinary Shares 2022-04-05 4 P 0 2850000 10.00 A 2850000 I See footnote Class B Ordinary Shares 2022-04-05 4 C 0 2785000 D Class A Ordinary Shares 2785000 0 I See footnote Helix Holdings LLC is the record holder of these securities reported. Bihua Chen is the manager of Helix Holdings LLC and has voting and investment discretion with respect to the securities held of record by Helix Holdings LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Each of the Issuer's Class B Ordinary Shares were convertible into Class A Ordinary Shares upon consummation of the Issuer's initial business combination and had no expiration date. In connection with the consummation of the Issuer's initial business combination ("Business Combination") and pursuant to the Business Combination Agreement dated as of October 4, 2021, by and between the Issuer, MoonLake Immunotherapeutics AG, and the other parties thereto (the "Business Combination Agreement"), such Class B Ordinary Shares automatically converted into an equal number of Class A Ordinary Shares. In connection with the Business Combination, the Cormorant Funds entered into Subscription Agreements with the Issuer dated as of October 4, 2021 and March 31, 2022, pursuant to which, at the closing of the Business Combination, the Cormorant Funds purchased an aggregate of 2,850,000 Class A Ordinary Shares at a price of $10.00 per share. /s/ Bihua Chen 2022-04-07